Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 8:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 46 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Talimogene Laherparepvec Clear all
Suspended Phase 2 Interventional Accepts healthy volunteers

Neoadjuvant T-VEC in High Risk Early Melanoma

NCT04427306
View directory record Official record
Conditions
Melanoma
Interventions
T-Vec
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Sep 14, 2023 · Synced Sep 9, 2026, 8:32 AM EDT
Recruiting Phase 2 Interventional

Neoadjuvant Combination Immunotherapy for Stage III Melanoma

NCT03842943
View directory record Official record
Conditions
Cutaneous Melanoma
Interventions
Pembrolizumab, Talimogene Laherparepvec
Drug
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated May 1, 2024 · Synced Sep 9, 2026, 8:32 AM EDT
Terminated Phase 1 Interventional Results available

Talimogene Laherparepvec and Panitumumab for the Treatment of Locally Advanced or Metastatic Squamous Cell Carcinoma of the Skin

NCT04163952
View directory record Official record
Conditions
Locally Advanced Skin Squamous Cell Carcinoma, Metastatic Skin Squamous Cell Carcinoma, Recurrent Skin Squamous Cell Carcinoma
Interventions
Panitumumab, Talimogene Laherparepvec
Biological
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
5
States / cities
New Brunswick, New Jersey • New York, New York • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Sep 9, 2026, 8:32 AM EDT
Active, not recruiting Phase 2 Interventional Results available

A Study of Talimogene Laherparepvec (T-VEC) in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma

NCT03069378
View directory record Official record
Conditions
Sarcoma, Epithelioid Sarcoma, Cutaneous Angiosarcoma
Interventions
Talimogene Laherparepvec (T-VEC), Pembrolizumab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
5
States / cities
Menlo Park, California • Stanford, California • Harrison, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Sep 9, 2026, 8:32 AM EDT
Completed Phase 1 Interventional Results available

Talimogene Laherparepvec With Pembrolizumab for Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY232 / KEYNOTE-137)

NCT02626000
View directory record Official record
Conditions
Carcinoma of the Head and Neck
Interventions
Talimogene Laherparepvec, Pembrolizumab
Drug · Biological
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
8
States / cities
Newark, Delaware • Chicago, Illinois • Louisville, Kentucky + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2021 · Synced Sep 9, 2026, 8:32 AM EDT
Completed Phase 2 Interventional Results available

A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors

NCT02819843
View directory record Official record
Conditions
Melanoma, Merkel Cell Carcinoma, Other Solid Tumors
Interventions
TALIMOGENE LAHERPAREPVEC (TVEC), Hypofractionated Radiotherapy
Drug · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
3
States / cities
Middletown, New Jersey • Harrison, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 28, 2025 · Synced Sep 9, 2026, 8:32 AM EDT
Completed Phase 3 Interventional Results available

An Extended Use Study of Safety and Efficacy of Talimogene Laherparepvec in Melanoma

NCT01368276
View directory record Official record
Conditions
Melanoma
Interventions
Talimogene Laherparepvec, Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF)
Biological · Drug
Lead sponsor
BioVex Limited
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
9
States / cities
Chicago, Illinois • Indianapolis, Indiana • Iowa City, Iowa + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2015 · Synced Sep 9, 2026, 8:32 AM EDT
Completed Phase 1 Interventional

T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer

NCT03554044
View directory record Official record
Conditions
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Positive, HER2/Neu Negative, Invasive Breast Carcinoma, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8, Recurrent Breast Carcinoma
Interventions
Anastrozole, Exemestane, Fulvestrant, Letrozole, Paclitaxel, Talimogene Laherparepvec, Tamoxifen, Nab paclitaxel, Gemcitabine, Carboplatin
Drug · Biological
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 20, 2025 · Synced Sep 9, 2026, 8:32 AM EDT
Completed Phase 2 Interventional Results available

Study of TVEC in Patients With Cutaneous Squamous Cell Cancer

NCT03714828
View directory record Official record
Conditions
Squamous Cell Carcinoma, Skin Cancer, Keratoacanthoma, Cutaneous Tumor, Skin Cancer, Squamous Cell, Lesion Skin
Interventions
Injection of TVEC into target lesions - week 1-2, Injection of TVEC into target lesions 3wks after 1st injection, Injection of TVEC into target lesions 2wks after 2nd injection, Injection of TVEC into target lesions 2wks after 3rd injection
Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
2
States / cities
Scottsdale, Arizona • Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Sep 9, 2026, 8:32 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Tumors Alone and in Combination With Systemic Pembrolizumab MK-3475-611/Keynote-611

NCT02509507
View directory record Official record
Conditions
Hepatocellular Carcinoma, Liver Metastases, Cutaneous or Subcutaneous Lymph Node, Liver Tumors
Interventions
Talimogene Laherparepvec, Pembrolizumab
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
9
States / cities
Scottsdale, Arizona • Santa Monica, California • Washington D.C., District of Columbia + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2024 · Synced Sep 9, 2026, 8:32 AM EDT
Completed Phase 2 Interventional Results available

Talimogene Laherparepvec With Pembrolizumab in Melanoma Following Progression on Prior Anti-PD-1 Based Therapy (MASTERKEY-115) (Mk-3475-A07/KEYNOTE-A07).

NCT04068181
View directory record Official record
Conditions
Melanoma
Interventions
Talimogene laherparepvec, Pembrolizumab
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 99 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
10
States / cities
Santa Barbara, California • Newark, Delaware • Orlando, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2025 · Synced Sep 9, 2026, 8:32 AM EDT
Terminated Phase 3 Interventional Results available

Pembrolizumab With Talimogene Laherparepvec or Placebo in Unresected Melanoma

NCT02263508
View directory record Official record
Conditions
Melanoma
Interventions
Talimogene Laherparepvec, Pembrolizumab, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 95 Years
Enrollment
713 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
41
States / cities
Birmingham, Alabama • Mobile, Alabama • Beverly Hills, California + 32 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2022 · Synced Sep 9, 2026, 8:32 AM EDT
Active, not recruiting Phase 2 Interventional

Neoadjuvant Intralesional Injection of Talimogene Laherparepvec

NCT06660810
View directory record Official record
Conditions
Soft Tissue Sarcoma, Sarcoma,Soft Tissue
Interventions
Talimogene Laherparepvec, Neoadjuvant Radiation, Surgery
Drug · Radiation · Procedure
Lead sponsor
John Rieth
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Sep 9, 2026, 8:32 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma

NCT00769704
View directory record Official record
Conditions
Melanoma
Interventions
Talimogene laherparepvec, GM-CSF
Biological
Lead sponsor
BioVex Limited
Industry
Eligibility
18 Years and older
Enrollment
437 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
57
States / cities
Tucson, Arizona • Little Rock, Arkansas • La Jolla, California + 50 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2016 · Synced Sep 9, 2026, 8:32 AM EDT
Completed Phase 2 Interventional Results available

A Study of Talimogene Laherparepvec in Stage IIIc and Stage IV Malignant Melanoma

NCT00289016
View directory record Official record
Conditions
Melanoma
Interventions
Talimogene Laherparepvec
Drug
Lead sponsor
BioVex Limited
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
7
States / cities
La Jolla, California • Los Angeles, California • Aurora, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2015 · Synced Sep 9, 2026, 8:32 AM EDT
Terminated Phase 1 Interventional

Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating Participants With Localized, Triple-Negative or Estrogen Receptor Positive, HER2 Negative Breast Cancer-deleted

NCT04185311
View directory record Official record
Conditions
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, HER2/Neu Negative, Invasive Ductal Carcinoma, Not Otherwise Specified, Progesterone Receptor Negative, Prognostic Stage 0 Breast Cancer AJCC v8, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma
Interventions
Ipilimumab, Nivolumab, Talimogene Laherparepvec
Biological
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Sep 9, 2026, 8:32 AM EDT
Terminated Phase 3 Interventional Results available

PV-10 vs Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma

NCT02288897
View directory record Official record
Conditions
Cutaneous Melanoma
Interventions
PV-10 (10% rose bengal disodium), Dacarbazine, temozolomide or talimogene laherparepvec
Drug
Lead sponsor
Provectus Biopharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
12
States / cities
San Diego, California • Miami Beach, Florida • Tampa, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2022 · Synced Sep 9, 2026, 8:32 AM EDT
Not listed Phase 1 Interventional

Combining Talimogene Laherparepvec With BRAF and MEK Inhibitors in BRAF Mutated Advanced Melanoma

NCT03088176
View directory record Official record
Conditions
Melanoma, BRAF Gene Mutation
Interventions
Talimogene Laherparepvec 1 Million Pfu/Ml Inj,Susp,1Ml,Vil, Talimogene Laherparep 100 Mil Pfu/Ml 1Ml, Dabrafenib, Trametinib
Drug
Lead sponsor
West Cancer Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Germantown, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 11, 2020 · Synced Sep 9, 2026, 8:32 AM EDT
Active, not recruiting Phase 2 Interventional

Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers

NCT02978625
View directory record Official record
Conditions
Anaplastic Large Cell Lymphoma, ALK-Negative, Anaplastic Large Cell Lymphoma, ALK-Positive, Apocrine Carcinoma, Carcinoma Arising From Cylindroma, Carcinoma Arising From Spiradenoma, Digital Papillary Adenocarcinoma, Endocrine Mucin-Producing Sweat Gland Carcinoma, Extramammary Paget Disease, Extraocular Sebaceous Carcinoma, Hidradenocarcinoma, Malignant Sweat Gland Neoplasm, Merkel Cell Carcinoma, Microcystic Adnexal Carcinoma, NK-Cell Lymphoma, Unclassifiable, Papillary Adenocarcinoma, Porocarcinoma, Primary Cutaneous Mucinous Carcinoma, Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Recurrent T-Cell Non-Hodgkin Lymphoma, Refractory Anaplastic Large Cell Lymphoma, Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Refractory Merkel Cell Carcinoma, Refractory Mycosis Fungoides, Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory Skin Squamous Cell Carcinoma, Refractory T-Cell Non-Hodgkin Lymphoma, Sezary Syndrome, Signet Ring Cell Adenocarcinoma, Skin Adenoid Cystic Carcinoma, Skin Adnexal Carcinoma, Skin Basal Cell Carcinoma, Skin Basosquamous Cell Carcinoma, Skin Keratoacanthoma, Skin Squamous Cell Carcinoma, Squamoid Eccrine Ductal Carcinoma, Squamous Cell Carcinoma of Unknown Primary, Sweat Gland Carcinoma, Trichilemmal Carcinoma, Vulvar Squamous Cell Carcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Laboratory Biomarker Analysis, Nivolumab, Positron Emission Mammography, Talimogene Laherparepvec
Procedure · Other · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
36
States / cities
Los Angeles, California • Orange, California • Pasadena, California + 28 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 9, 2026, 8:32 AM EDT
Completed Phase 1 Interventional Results available

Talimogene Laherparepvec for the Treatment of Peritoneal Surface Malignancies

NCT03663712
View directory record Official record
Conditions
Peritoneal Surface Malignancy
Interventions
Talimogene Laherparepvec
Biological
Lead sponsor
Dan Blazer III, M.D.
Other
Eligibility
18 Years to 99 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
3
States / cities
Chicago, Illinois • Durham, North Carolina • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Sep 9, 2026, 8:32 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Talimogene Laherparepvec Neoadjuvant Treatment Plus Surgery Versus Surgery Alone for Melanoma

NCT02211131
View directory record Official record
Conditions
Completely Resectable Stage IIIB, IIIC, or IVM1a Melanoma
Interventions
Talimogene Laherparepvec, Immediate surgical resection of melanoma lesion(s)
Drug · Procedure
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
22
States / cities
Birmingham, Alabama • Duarte, California • Orange, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2023 · Synced Sep 9, 2026, 8:32 AM EDT
Completed Phase 2 Interventional Results available

Single-arm Trial to Evaluate the Role of the Immune Response to Talimogene Laherparepvec in Unresected Melanoma

NCT02366195
View directory record Official record
Conditions
Unresected Stage IIIb to IVM1c Melanoma
Interventions
Talimogene Laherparepvec
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Nov 29, 2021 · Synced Sep 9, 2026, 8:32 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

TVEC and Preop Radiation for Sarcoma (8 ml Dose)

NCT04599062
View directory record Official record
Conditions
Soft Tissue Sarcoma
Interventions
Talimogene Laherparepvec, Radiotherapy
Drug · Radiation
Lead sponsor
John Rieth
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Sep 9, 2026, 8:32 AM EDT
Terminated Phase 2 Interventional Results available

Study of T-VEC in Locally Advanced Cutaneous Angiosarcoma

NCT03921073
View directory record Official record
Conditions
Angiosarcoma of Skin
Interventions
T-VEC
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Oct 31, 2022 · Synced Sep 9, 2026, 8:32 AM EDT